HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The polyadenylation inhibitor cordycepin reduces pain, inflammation and joint pathology in rodent models of osteoarthritis.

Abstract
Clinically, osteoarthritis (OA) pain is significantly associated with synovial inflammation. Identification of the mechanisms driving inflammation could reveal new targets to relieve this prevalent pain state. Herein, a role of polyadenylation in OA synovial samples was investigated, and the potential of the polyadenylation inhibitor cordycepin (3' deoxyadenosine) to inhibit inflammation as well as to reduce pain and structural OA progression were studied. Joint tissues from people with OA with high or low grade inflammation and non-arthritic post-mortem controls were analysed for the polyadenylation factor CPSF4 and inflammatory markers. Effects of cordycepin on pain behavior and joint pathology were studied in models of OA (intra-articular injection of monosodium iodoacetate in rats and surgical destabilisation of the medial meniscus in mice). Human monocyte-derived macrophages and a mouse macrophage cell line were used to determine effects of cordycepin on nuclear localisation of the inflammatory transcription factor NFĸB and polyadenylation factors (WDR33 and CPSF4). CPSF4 and NFκB expression were increased in synovia from OA patients with high grade inflammation. Cordycepin reduced pain behaviour, synovial inflammation and joint pathology in both OA models. Stimulation of macrophages induced nuclear localisation of NFĸB and polyadenylation factors, effects inhibited by cordycepin. Knockdown of polyadenylation factors also prevented nuclear localisation of NFĸB. The increased expression of polyadenylation factors in OA synovia indicates a new target for analgesia treatments. This is supported by the finding that polyadenylation factors are required for inflammation in macrophages and by the fact that the polyadenylation inhibitor cordycepin attenuates pain and pathology in models of OA.
AuthorsSadaf Ashraf, Masar Radhi, Peter Gowler, James J Burston, Raj D Gandhi, Graeme J Thorn, Anna M Piccinini, David A Walsh, Victoria Chapman, Cornelia H de Moor
JournalScientific reports (Sci Rep) Vol. 9 Issue 1 Pg. 4696 (03 18 2019) ISSN: 2045-2322 [Electronic] England
PMID30886197 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Deoxyadenosines
  • NF-kappa B
  • cordycepin
Topics
  • Animals
  • Arthritis, Experimental (drug therapy)
  • Deoxyadenosines (therapeutic use)
  • Disease Models, Animal
  • Humans
  • Inflammation (drug therapy)
  • Joints (drug effects, pathology)
  • Mice
  • NF-kappa B (metabolism)
  • Osteoarthritis (drug therapy)
  • Pain (drug therapy)
  • Polyadenylation
  • Rats
  • Signal Transduction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: